Biotechnology

Gyre Therapeutics

Gyre Therapeutics released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 22.52 M (forecast USD 31.61 M), actual EPS USD -0.0999 (forecast USD -0.0733)

Gyre Therapeutics released FY2025 Q4 earnings on March 12 (EST), actual revenue USD 37.2 M (forecast USD 35.44 M), actual EPS USD -0.0217 (forecast USD 0.0533)

Gyre Therapeutics released FY2025 Annual Earnings on March 12 (EST), actual revenue USD 116.59 M (forecast USD 114.83 M), actual EPS USD 0.0224 (forecast USD 0.15)

Gyre Therapeutics Demonstrates Leadership in China's IPF Treatment Market and Expands Treatment Options

Gyre Therapeutics released FY2025 9 Months Earnings on November 7 (EST), actual revenue USD 79.39 M, actual EPS USD 0.0415

Gyre Therapeutics released FY2025 Q3 earnings on November 7 (EST), actual revenue USD 30.56 M (forecast USD 32.93 M), actual EPS USD 0.0349 (forecast USD 0.0266)

Analyst LeBoyer Reiterates Strong Buy Rating for Gyre Therapeutics

Keller's performance in healthcare stock investments

Gyre Therapeutics to Present Third-Stage Clinical Trial Results of Hydronidone at the Liver Meeting

Gyre Therapeutics released FY2025 Q2 earnings on August 11 EST, actual revenue USD 26.77 M (forecast USD 30.8 M), actual EPS USD 0.0022 (forecast USD 0.03)

Gyre Therapeutics released FY2025 Semi-Annual earnings on August 11 (EST), actual revenue USD 48.83 M, actual EPS USD 0.0066

Gyre Therapeutics Launches F230 Clinical Trial for Pulmonary Arterial Hypertension

Gyre Therapeutics Inc. President and Director Ma Songjiang Disposes of Company Common Stock

Gyre Therapeutics Raises $23 Million in Public Offering

Gyre Therapeutics Price Public Offering

Gyre Therapeutics Inc. Conducts Underwritten Public Offering of Common Stock

Gyre Therapeutics' Hydronidone Phase III Clinical Trial Successful

Ma Songjiang Sells Gyre Therapeutics Inc. Stock

Ma Songjiang, President and Director of Gyre Therapeutics Inc., Disposes of Common Stock

Gyre Therapeutics released FY2025 Q1 earnings on May 9, 2025 (EST), actual revenue USD 22.06 M (forecast USD 28.4 M), actual EPS USD 0.0043 (forecast USD 0.03)

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

GYRE

Gyre Therapeutics COO Weiguo Ye sold 9,320 shares at weighted-average prices of $6.62 and $6.37, reducing his stake to 700,000 shares. The shares were sold following option exercises at $0.75 per share on May 18-19.

PUBT

Gyre COO Ye Weiguo sells USD 59,833 Gyre Therapeutics shares

Gyre Therapeutics will present preclinical data on CG923308 at a Shanghai conference, highlighting its potent anti-tumor activity and oral bioavailability. The company aims to leverage its collaboration with Cullgen for accelerated development and anticipates submitting an IND for CG923308 in Q1 2027. The presentation includes a detailed slide deck on their pipeline and strategy.

TradingView

Gyre Therapeutics to present CG923308 data; expects IND submission Q1 2027

Earnings Watch

Gyre Therapeutics | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 22.52 M

Gyre Therapeutics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 22.52 M

Ying Luo, CEO of Gyre Therapeutics (NASDAQ:GYRE), sold 10,136 shares at an average price of $8.04, totaling $81,493.44. Post-sale, he holds 2,565,226 shares valued at approximately $20.62 million, marking a 0.39% decrease in ownership. The sale was disclosed to the SEC. Gyre's stock recently traded at $7.07, with a market cap of $685.72 million. The company reported a quarterly loss of $0.10 per share, missing estimates. Analysts have mixed ratings on the stock, with an average target price of $17.00.

Market Beat

Bank of NY Mellon

Barclays

Charles Schwab

State Street

NASDAQ Composite Index

NASDAQ-100

BANK OF NEW YORK MELLON CORP DEP SHS REPG 1/4000TH INT SER K PFD

SCHWAB(CHARLES)CORP 5.95% DEP SHS REP 1/40 NON CUM PERP PF D

SCHWAB(CHARLES)CORP 4.450% DEP SHS REP 1/40TH N-CUM PFD SERJ

State Street® US Equity Premium Inc ETF

Ying Luo Sells 10,136 Shares of Gyre Therapeutics (NASDAQ:GYRE) Stock

Shares of Gyre Therapeutics (NASDAQ:GYRE) fell 11.4% to $7.1250 following disappointing earnings, missing EPS estimates by $0.04 and reporting revenue of $22.52 million, below the expected $31.61 million. Analysts have downgraded the stock, with Zacks Research changing its rating from "hold" to "strong sell". Institutional investors own 23.99% of the company, which has a market cap of $686.20 million and a P/E ratio of 708.31. Gyre focuses on developing therapies targeting lipid biology for various diseases.

Gyre Therapeutics (NASDAQ:GYRE)  Shares Down 11.4%  on Disappointing Earnings

Gyre Therapeutics shares are trading lower after the company reported worse-than-expected Q1 sales results.

benzinga_article

Gyre Therapeutics has completed its acquisition of Cullgen in an all-stock deal valued at approximately $300 million, creating a fully integrated biopharmaceutical company based in the U.S. and China. The combined entity will focus on fibrosis and inflammatory diseases, leveraging a commercial asset and a robust pipeline, including the lead product candidate F351 for chronic hepatitis B-induced liver fibrosis. Dr. Ying Luo has been appointed as CEO, and the company will continue trading on Nasdaq under the ticker GYRE.

StockTitan

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company | GYRE Stock News

Gyre Therapeutics(GYRE.US)